Efficacy and tolerability of moxifloxacin in patients with respiratory tract infections treated in general practice: Results of a post-marketing surveillance study

Clinical Drug Investigation

Volumn 26, Issue 9, 2006, Pages 501-509

  Chen, Weiqiang ^a   Wu, Changgui ^a   Li, Zhikui ^a   Bai, Changqing ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN;

ADULT; AGED; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CHINA; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENERAL PRACTICE; HEADACHE; HUMAN; INFORMATION PROCESSING; LUNG AUSCULTATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPEN STUDY; PATIENT ATTITUDE; PHYSICIAN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY TRACT INFECTION; TREATMENT OUTCOME;

ADULT; AGED; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; FAMILY PRACTICE; FEMALE; HUMANS; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; QUINOLINES; RESPIRATORY TRACT INFECTIONS;

EID: 33747392552     PISSN: 11732563     EISSN: 11732563     Source Type: Journal    
DOI: 10.2165/00044011-200626090-00003     Document Type: Article

References (28)

1. Landen H, Bauer T. Efficacy, onset of action and tolerability of moxifloxacin in patients with community-acquired pneumonia. Clin Drug Invest 2001; 21 (12): 801-11
2. Briel M, Langewitz W, Tschudi P, et al. Communication training and antibiotic use in acute respiratory tract infections: a cluster randomised controlled trial in general practice. Swiss Med Wkly 2006 Apr 15; 136 (15-16): 241-7
3. Epstein BJ, Gums JG. Optimal pharmacological therapy for community-acquired pneumonia: the role of dual antibacterial therapy. Drugs 2005; 65 (14): 1949-71
4. Segreti J, House HR, Siegel RE. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting. Am J Med 2005 Jul; 118 Suppl. 7A: 21S-8S
5. Apisarnthanarak A, Mundy LM. Etiology of community-acquired pneumonia. Clin Chest Med. 2005 Mar; 26 (1): 47-55
6. Guthrie R. Community-acquired lower respiratory tract infections: etiology and treatment. Chest 2001 Dec; 120 (6): 2021-34
7. Lode H, Lubasch A, Raffenberg M, et al. Clinical results in the treatment of respiratory infections with moxifloxacin. Drugs Today (Barc) 2000 Apr; 36 (4): 245-53
8. Klugman KP, Capper T. Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin. J Antimicrob Chemother 1997; 40: 797-802
9. Krasemann C, Meyer J, Tillotson G. Evaluation of the clinical microbiology profile of moxifloxacin. Clin Infect Dis 2001; 32 Suppl. 1: S51-63
10. Gwaltney Jr JM. Acute community-acquired sinusitis. Clin Infect Dis 1996; 23: 1209-23
11. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000; 117: 380S-5S
12. Blondeau JM, Laskowski R, Bjarnason J, et al. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms. Int J Antimicrob Agents 2000; 14: 45-50
13. Ulrich M, Berger J, Moller JG, Doring G. Moxifloxacin and ciprofloxacin protect human respiratory epithelial cells against Streptococcus pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, and Haemophilus influenzae in vitro. Infection 2005 Dec; 33 Suppl. 2: 50-4.
14. Barth J, Landen H. Efficacy and tolerability of moxifloxacin in 2338 patients with acute exacerbation of chronic bronchitis. Clin Drug Invest 2003; 23 (1): 1-10
15. Aydemir S, Tunger A, Cilli F. In vitro activity of fluoroquinolones against common respiratory pathogens. West Indian Med J 2006 Jan; 55(1): 9-12
16. Landen H, Moller M, Tillotson GS, et al. Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin. J Int Med Res 2001; 29: 51-60
17. Wilson R, Allegra L, Huchon G, et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004 Mar; 125 (3): 953-64
18. Bauer T, Landen H, Stauch K. Rapid resolution of symptoms with moxifloxacin therapy in 7223 patients with acute exacerbation of chronic bronchitis: comparison with prior macrolide treatment. Clin Drug Invest 2002; 22: 641-51
19. Chodosh S, DeAbate CA, Haverstock D, et al. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Respir Med 2000; 94: 18-27
20. Petitpretz P, Arvis P, Marel M, et al. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 2001; 119: 185-95
21. Finch R, Schürmann D, Collins O, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002; 46: 1746-54
22. Liu YN, Chen MJ, Zhao TM, et al. A multicentre study on the pathogenic agents in 665 adult patients with community-acquired pneumonia in cities of China. Zhonghua Jie He He Hu Xi Za Zhi 2006 Jan; 29 (1): 3-8
23. Song JH, Jung SI, Ki HK, et al. Asian Network for Surveillance of Resistant Pathogens Study Group. Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in Asian countries: a study by the Asian Network for Surveillance of Resistant Pathogens. Clin Infect Dis 2004 Jun 1; 38 (11): 1570-8
24. Siegert R, Gehanno P, Nikolaidis P, et al. A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group. Respir Med 2000 Apr; 94 (4): 337-44
25. Lode H, Kubin R, Reiter C. Safety update of oral moxifloxacin: a review of worldwide post-marketing surveillance. Clin Microbiol Infect 2002; 8 Suppl. 1: 323-4
26. Finch R, Schurmann D, Collins O, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002; 46: 1746-54
27. Malangoni MA, Song J, Herrington J, et al. Randomised controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Annals of Surgery 2006; 244: 204-11
28. Stass H, Kubitza D. Lack of pharmacokinetic interaction between moxifloxacin, a novel 8-methoxyfluoroquinolone, and theophylline. Clin Pharmacokinet 2001; 40 Suppl. 1: 63-70